Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab

Phase 2

Completed

• Conditions: Macular Edema; Diabetic Retinopathy; Macular Degeneration

• Registration Number: NCT00804921
• Lead Sponsor: University of Sao Paulo

Brief Summary

Purpose: To evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure (IOP) variations after intravitreal bevacizumab injection (IVBV).

Methods: 47 patients scheduled for IVBV (1.5 mg / 0.06 ml) will be randomly assigned to a pre-treatment 1 hour before IVBV with either 250 mg oral acetazolamide (DIA, 9 eyes), anterior chamber paracentesis immediate after IVBV (PAR, 15 eyes), topic brimonidine tartarate 1 hour before IVBV (BRI, 14 eyes), or no pre-treatment IBVB (CTR, 9 eyes). IOP will be measured 90 minutes before injection (baseline), just before injection, and at 3, 10, 20 and 30 minutes after the procedure.

Detailed Description

Not available

Study Timeline

• Status Verified: 2008-12
• Study First Submitted: 2008-12-08
• Study First Submitted QC: 2008-12-08
• Last Update Submitted: 2008-12-08
• Study First Posted: 2008-12-09
• Last Update Posted: 2008-12-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• macular edema

Exclusion Criteria

• pulmonary chronic problems
• chronic renal failure
• intraocular inflammation
• drug or alcohol addiction

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intra-ocular pressure variation after intra-vitreous injection of bevacizumab

Trial Locations

Locations (1)

School of Medicine - Clinical Hospital; 🇧🇷 Ribeirao Preto, SP, Brazil